HOME >> BIOLOGY >> NEWS
Temple University researchers develop new targeted cancer therapy

Temple University researchers have developed a new drug that halts cancer cell division, instigating tumor death. The drug works by interfering with the activity of a gene called Plk1 and is now in phase I clinical trials for human cancer therapy. Their research is published in the March issue of Cancer Cell.

Plk1 is one of several molecules that play a critical role in the spread of cancer. Previous studies have found higher levels of Plk1 in cancer tumors and in patients with poorer survival rates. When Plk1 activity was blocked, cancer cells could not divide and tumors could not survive.

Led by Prem Reddy, Ph.D., professor of biochemistry and director of the Fels Institute for Cancer Research at Temple University School of Medicine, the Temple team sought out a new compound that would target and block Plk1. They developed and tested ON01910, a small molecule that inhibits Plk1 activity, on 94 different human cancers. "We found that ON01910 was a potent inhibitor of human tumor growth and also worked well with several existing cancer drugs, often inducing complete regression of tumors. Someday it might work either as a single drug or in combination with other drugs," said Reddy.

Johns Hopkins Medicine and Mt. Sinai Medical Center are currently conducting the first clinical trial of ON01910 in patients with advanced and metastatic cancers. The studies will evaluate data from up to 56 patients. ON01910 is known as a targeted therapy, a new area of cancer drug research and development. As the name suggests, such therapies target molecules that are critical to a tumor's survival. Targeted therapies block the molecules from functioning, thereby preventing tumors from surviving.

On the unique actions of ON01910, Reddy said, "Our drug stops tumor cells from reaching normal cells three ways. First, it blocks invasion, next it blocks angiogenesis and finally, it induces tumor cell death. It also appears to be very safe." Other research t
'"/>

Contact: Eryn Jelesiewicz
dobeck@temple.edu
215-707-0730
Temple University
14-Mar-2005


Page: 1 2

Related biology news :

1. Third annual Templeton-Cambridge Fellowships awarded to 10 noted journalists
2. John Templeton Foundation awards $2.8 million to examine origins of biological complexity
3. Temple engineers recieve NSF grant to develop interactive high school biology curriculum
4. SHRO signs agreement with Temple to continue biomedical research
5. Temple virologist receives $6.1 million NIH grant for neuro-AIDS research
6. NIH gives $8M to University of Pittsburgh School of Medicine for myositis research
7. A study by the MUHC and McGill University opens a new door to understanding cancer
8. Biologists at Tufts University discover 1 reason why chromosomes break, often leading to cancer
9. $9M grant awarded to University of Cincinnati for bipolar disorder research
10. University of Leeds strengthens China links in membrane and neurobiology
11. University of Colorado licenses two influenza virus detection discoveries to Quidel Corp.

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/14/2019)... ... 2019 , ... Highmark Health’s VITAL Innovation Platform has been named the winner ... is one of the top honors in the awards. Winners were announced at an ... a community event on May 10 that also raises funds for Carnegie Science Center ...
(Date:3/11/2019)... ... March 11, 2019 , ... A new report published by the Family Equality ... generations; 77% of those aged 18 to 35 already have or are considering having ... 55 and older.(1) Among all LGBTQ prospective parents, 41% are considering assisted reproductive technology ...
(Date:3/9/2019)... British Columbia (PRWEB) , ... March 07, 2019 ... ... specializing in manufacturing neurological and cellular stress research tools today announced the publication ... antibody for Parkinson’s Disease treatment. The antibody, still at a pre-clinical stage of ...
Breaking Biology News(10 mins):
(Date:3/14/2019)... ... March 14, 2019 , ... ON NOVEMBER 27, 2018, ... the Eye Machine Canada Inc., had been given approval to begin a clinical ... Macular Degeneration (AMD). , The previous month, the medical devices bureau of Health ...
(Date:3/12/2019)... N.J. and LIÈGE, Belgium (PRWEB) , ... March ... ... complete solutions for sample preparation and epigenetics research, has launched its third generation ... features of the second generation instrument with a user-friendly interface, automated processing, ...
(Date:3/5/2019)... ... March 05, 2019 , ... San Fransisko, or Sisko for short, is a ... years old to pursue a career in dressage. According to Deborah, dressage came ... that she’d ever worked with. Unfortunately, Sisko suffered an injury while playing in ...
(Date:2/26/2019)... WHITEHOUSE, N.J. (PRWEB) , ... February 26, 2019 ... ... University in 2012 when Visikol Co-Founder Dr. Thomas Villani developed the Visikol® tissue ... a company and has since transitioned from a products focused company to primarily ...
Breaking Biology Technology:
Cached News: